ArticleEClinicalMedicine2026
Trends in the incidence of atrial fibrillation and the prescription of oral anticoagulants in adults with chronic obstructive pulmonary disease in UK primary care (2010-2022): a cohort study.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Understanding the burden of atrial fibrillation (AF) and oral anticoagulant (OAC) use in patients with chronic obstructive pulmonary disease (COPD) is important for stroke prevention in this high-risk population. We assessed trends in AF incidence and OAC initiation among patients with COPD in UK primary care from 2010 to 2022. Methods: We assembled a cohort of all patients at least 50 years of age who contributed data to the UK Clinical Practice Research Datalink between January 1, 2010, and December 31, 2022, who had a physician diagnosis of COPD before or during the study period. Patients were followed-up until AF diagnosis, study end date (December 2022), death, or transfer out of practice. We estimated annual incidence rates of AF and subsequent OAC initiation using Poisson regression, stratified by age, sex, ethnicity, and COPD severity. We assessed predictors of AF and OAC initiation using Cox proportional hazards regression models. Findings: 444,668 patients with COPD were included (mean age 70 years, 51.8% male), contributing 2,284,799 person-years of follow-up. 37,645 (8.5%) patients were diagnosed with AF during the study period. The incidence of AF increased from 13.8 per 1000 person-years in 2010 to 19.3 in 2022 [rate ratio (RR) 1.29; 95% confidence interval (CI) 1.07-1.56], and was higher in males, White individuals, those over 80 years, and patients with severe COPD. Only 23,094 patients (66.3%) were prescribed an OAC in the year following AF diagnosis, though OAC use increased 2.9-fold during this period (RR 2.91; 95% CI 2.33-3.65). OAC initiation remained lowest among patients aged 50-59 and ≥90 years, and non-White individuals. OAC use was also up to 25.0% (adjusted hazard ratio 0.75; 95% CI 0.69, 0.81) less prevalent among those with severe COPD. Interpretation: AF incidence and OAC initiation increased among patients with COPD in UK primary care over 2010-2022. However, OAC use remained suboptimal, especially among older patients, non-White individuals, and those with severe COPD. These potential treatment gaps highlight the need for further research on stroke prevention strategies in this high-risk population. Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.